Clinical Trials Logo
  1. Home
  2. Autism Spectrum Disorder (ASD)
  3. NCT01395953

Double-blind Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders

Autism Spectrum Disorder (ASD) Clinical Trial

Official title:
Double-blind Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders

Clinical Trial Summary

The main objective of this exploratory 8 week pilot study is to evaluate the safety and efficacy of buspirone for the treatment of anxiety in youth (ages 6-17 years) with autism spectrum disorders. The study results will be used to generate hypotheses for a larger randomized controlled clinical trial with explicit hypotheses and sufficient statistical power.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01395953
Study type Interventional
Source Massachusetts General Hospital
Contact
Status Withdrawn
Phase Phase 2
Start date November 2011
Completion date July 2013
View Details
See also
  Status Clinical Trial Phase
Terminated NCT03715166 - Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder Phase 3
Not yet recruiting NCT05182697 - SCI-210 in the Treatment of Children and Young Adults With AutismEvaluate the Safety, Tolerability and Efficacy of SCI-210 in Children With Autism Spectrum Disorder (ASD) N/A
Completed NCT02803801 - Build Your Parenting Toolkit: Guiding Children to Become Flexible Thinkers N/A
Recruiting NCT04376151 - Guided ACT and for Adults With ASD N/A
Terminated NCT03715153 - Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder. Phase 3
Terminated NCT01592773 - Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Phase 2
Terminated NCT01248130 - Omega-3 Fatty Acids Monotherapy in Children and Adolescents With Autism Spectrum Disorders Phase 2
Completed NCT04860986 - A Repeatability and Reproducibility Study of the EarliPoint™ Device
Completed NCT04299464 - A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD) Phase 2
Recruiting NCT03392870 - Evaluation of a Clinical Transitional Program in Autism N/A
Completed NCT01592786 - An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Phase 2
Enrolling by invitation NCT05187377 - A Controlled Trial of Growth Hormone in Phelan-McDermid Syndrome and Idiopathic Autism Phase 2
Completed NCT04631432 - Choice Switching and Autism
Recruiting NCT04578756 - Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder Phase 3
Recruiting NCT06443320 - Evaluation of the Videodrama Therapeutic Device for Children With Autism Spectrum Disorders N/A
Completed NCT02037022 - Pivotal Response Treatment Package for Young Children With Autism N/A
Completed NCT01854346 - Social Skills Group Training ("KONTAKT") for Children and Adolescent With High-functioning Autism Spectrum Disorders N/A
Active, not recruiting NCT04895215 - AB-2004 in Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) Phase 2
Active, not recruiting NCT03426826 - The Gut-Brain Study Phase 1
Completed NCT02384486 - Efficacy of Training Programme to Reduce Stress N/A